Business Context and Reporting Period
This Form 6-K filing by GSK plc, a global biopharma company, covers the month of December 2025. The report was issued on December 1, 2025, from London, UK, to comply with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding share capital and voting rights rather than a financial performance report.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document focuses on the static calculation of voting rights as of November 30, 2025.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, risk factors, or contingencies. It serves solely to inform shareholders of the total voting rights denominator required for calculating disclosure thresholds under FCA rules.
Important Facts for Investors
- Total Issued Share Capital: As of November 30, 2025, GSK plc had 4,315,433,684 Ordinary Shares of 31.25 pence each.
- Treasury Shares: 236,608,577 Ordinary Shares were held in Treasury.
- Total Voting Rights: The total number of voting rights is 4,078,825,107.
- Regulatory Use: Shareholders must use the 4,078,825,107 figure as the denominator to determine if they are required to notify the Company of their interest or changes thereto.
- Contact for Notifications: Notifications should be sent to company.secretary@gsk.com.